NCT00274924 is a Phase 2 clinical trial of filgrastim in Lymphoma, sponsored by Eastern Cooperative Oncology Group.

Who is sponsoring NCT00274924?

NCT00274924 is sponsored by Eastern Cooperative Oncology Group.

What drugs are being tested in NCT00274924?

Interventions in NCT00274924: filgrastim, rituximab, carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, ifosfamide, prednisone, vincristine.

Is NCT00274924 still recruiting?

NCT00274924 is currently completed. Last updated 15 June 2023.

Are results published for NCT00274924?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2023-06-15 · How we verify

NCT00274924

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Response-Adapted Therapy for Aggressive Non-Hodgkin's Lymphomas Based on Early [18F] FDG-PET Scanning

Completed Phase 2 Results posted Last updated 15 June 2023

What this trial tests

Phase 2 trial testing filgrastim in Lymphoma in 100 participants. Completed in 1 March 2019.

Timeline

26 September 2006

Primary endpoint
1 June 2013

1 March 2019

Quick facts

Lead sponsor	Eastern Cooperative Oncology Group
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	100
Start date	26 September 2006
Primary completion	1 June 2013
Estimated completion	1 March 2019
Sites	104 locations across United States

Drugs / interventions tested

filgrastim
rituximab
carboplatin (Carboplatin) — full drug profile →
cyclophosphamide (cyclophosphamide) — full drug profile →
doxorubicin hydrochloride — full drug profile →
etoposide
ifosfamide
prednisone (prednisone) — full drug profile →
vincristine (vincristine) — full drug profile →

Conditions studied

Lymphoma — all drugs for Lymphoma →

Sponsor

Eastern Cooperative Oncology Group

Who can join

Adults 18 to 70, any sex, with Lymphoma. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

2-year Progression-Free Survival (PFS)
Time frame: Assessed every 4 months if patient is < 2 years from study entry, every 6 months if patient is 2-5 years from study entry, then every 12 months if patient is 5-10 years from study entry.
2-year progression-free survival is defined as the probability of patients who remain alive and progression free at 2 years from study entry. The method of Kaplan and Meier (1958) was used to estimate PFS.

Sponsor's own description

RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving rituximab together with combination chemotherapy may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving rituximab together with combination chemotherapy works in treating patients with stage II, stage III, or stage IV diffuse large B-cell non-Hodgkin's lymphoma.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study.
Horning SJ, Juweid ME, Schöder H, Wiseman G, et al · · 2010 · cited 87× · PMID 19767508 · DOI 10.1182/blood-2009-08-234351
Horning SJ, Juweid ME, Schöder H, et al. Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study. Blood. 2010;115(4):775–777.
· 2012

Verify or expand the search:

Other trials of filgrastim

Trials testing the same drug.

NCT06926751 — Telpegfilgrastim vs Filgrastim for Secondary Prevention of Chemotherapy-Induced Neutropenia in Pediatric Solid Tumors · Phase 2 · not yet recruiting
NCT04023669 — Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Re · Phase 1 · completed
NCT03434262 — SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children · Phase 1 · completed
NCT02029638 — BMT and High Dose Post-Transplant Cyclophosphamide for Chimerism Induction and Renal Allograft Tolerance · Phase 2 · terminated
NCT01707004 — Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients · Phase 2 · completed

Other recruiting trials for Lymphoma

Currently open trials in the same condition.

NCT07302347 — A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participan · Phase 1, PHASE2 · recruiting
NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
NCT06856226 — Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing · recruiting
NCT07226934 — An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers · NA · recruiting
NCT07138547 — GSL Synthetase Inhibitor Eliglustat Combined With CD30 Target Immunotherapy for the Treatment of of CD30+ Lymphoma · Phase 1, PHASE2 · recruiting

Other Eastern Cooperative Oncology Group trials

Trials by the same sponsor.

NCT07068074 — A Randomized Phase III Study of Management of Treatment Naive Primary Melanoma in Elderly Patients · Phase 3 · not yet recruiting
NCT07040280 — Testing the Effect of Sulforaphane, a Compound Naturally Found in Cruciferous Vegetables, on Preventing Melanoma in Pati · Phase 2 · not yet recruiting
NCT07122492 — A Targeted Electronic Health Approach to Reduce Fear of Recurrence in Breast Cancer Survivors (FoRtitude) · NA · not yet recruiting
NCT07085728 — Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatm · Phase 2 · not yet recruiting
NCT06756607 — The ECOG-ACRIN SUPPORT Trial: Multilevel Intervention to Improve Diverse Enrollment in Cancer Clinical Trials · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00274924 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Eastern Cooperative Oncology Group
Last refreshed: 15 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00274924.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing